Cargando…
OnabotulinumtoxinA: Still the Present for Chronic Migraine
OnabotulinumtoxinA (BT-A) is one of the few drugs approved for the preventive treatment of chronic migraine (CM). Despite this, some aspects of its mechanism of action are still a matter of debate, and the precise magnitude of BT-A effects needs to be completely elucidated. BT-A acts primarily upon...
Autores principales: | Baraldi, Carlo, Lo Castro, Flavia, Ornello, Raffaele, Sacco, Simona, Pani, Luca, Guerzoni, Simona |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9865956/ https://www.ncbi.nlm.nih.gov/pubmed/36668879 http://dx.doi.org/10.3390/toxins15010059 |
Ejemplares similares
-
Chronic Migraine and Medication Overuse Headache Worsening After OnabotulinumtoxinA Withdrawn Due to the Severe Acute Respiratory Syndrome-Coronavirus-2 Pandemic
por: Baraldi, Carlo, et al.
Publicado: (2021) -
Sustained response to onabotulinumtoxin A in patients with chronic migraine: real-life data
por: Ornello, Raffaele, et al.
Publicado: (2020) -
P045. OnabotulinumtoxinA: long term treatment for chronic migraine with medication overuse
por: Guerzoni, Simona, et al.
Publicado: (2015) -
Excellent Response to OnabotulinumtoxinA: Different Definitions, Different Predictors
por: Ornello, Raffaele, et al.
Publicado: (2022) -
Early Management of OnabotulinumtoxinA Treatment in Chronic Migraine: Insights from a Real-Life European Multicenter Study
por: Ornello, Raffaele, et al.
Publicado: (2021)